Q3 2024 Genomma Lab Internacional SAB de CV Earnings Call Transcript
Are subject to risks and uncertainties that could cause actual results to differ materially. They are also based on assumptions as of today and the company undertakes no obligation to update them as a result of new information or future events. Let me now turn the call over to Marco.
Good morning, everyone, and thank you, Chris. I am thrilled to share our strong Q 3 2024 results.
This quarter, we have seen substantial progress across all key metrics surpassing last year's results. Previous periods and our internal targets sales increased by 15.9% driven by excellent performance in major markets such as Mexico, Brazil, Argentina and the US gross margin improved by 184 basis points reaching 64.3%.
EBITDA expanded by 245 basis points reaching [23.7%] fueled by our productivity initiatives and manufacturing efficiencies.
Net income surged by 78.1% and earnings per share
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |